Apricoxib Terminated Phase N/A Trials for Non-Small Cell Lung Carcinoma (NSCLC) Prevention

IndicationsStatusPurposePhase
TerminatedPreventionNot Available
clinicaltrials.gov IdentifierTitleDrugs
NCT01532362Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer